Bausch Health Companies (NYSE:BHC) Stock Price Down 5.5% - Time to Sell?

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report)'s share price fell 5.5% on Wednesday . The stock traded as low as $4.47 and last traded at $4.55. 544,805 shares were traded during trading, a decline of 80% from the average session volume of 2,719,138 shares. The stock had previously closed at $4.81.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on BHC shares. Jefferies Financial Group reiterated a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada cut their target price on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a research report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.17.

Bausch Health Companies Stock Performance

The stock's 50-day simple moving average is $6.53 and its 200 day simple moving average is $7.53. The company has a market capitalization of $1.59 billion, a PE ratio of -36.08, a P/E/G ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The firm had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BHC. Vanguard Group Inc. boosted its position in shares of Bausch Health Companies by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock worth $94,460,000 after acquiring an additional 145,078 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Bausch Health Companies by 1.1% in the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company's stock worth $42,855,000 after acquiring an additional 56,446 shares during the period. Maple Rock Capital Partners Inc. grew its holdings in Bausch Health Companies by 156.7% during the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock valued at $42,718,000 after purchasing an additional 3,235,100 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Bausch Health Companies by 46.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock worth $38,501,000 after acquiring an additional 1,510,445 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after buying an additional 1,263,706 shares during the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.